MedPath
HSA Approval

DHACTULOSE SYRUP

SIN11494P

DHACTULOSE SYRUP

DHACTULOSE SYRUP

April 25, 2001

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence HolderTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

A06AD11

lactulose

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

PT Actavis Indonesia

Active Ingredients

LACTULOSE

3.35 g/5 ml

Lactulose

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DHACTULOSE SYRUP - HSA Approval | MedPath